ATE216891T1 - Verwendung von immunosuppressiva zur behandlung der schizophrenie - Google Patents

Verwendung von immunosuppressiva zur behandlung der schizophrenie

Info

Publication number
ATE216891T1
ATE216891T1 AT95924223T AT95924223T ATE216891T1 AT E216891 T1 ATE216891 T1 AT E216891T1 AT 95924223 T AT95924223 T AT 95924223T AT 95924223 T AT95924223 T AT 95924223T AT E216891 T1 ATE216891 T1 AT E216891T1
Authority
AT
Austria
Prior art keywords
pct
immunosuppressants
sec
treat schizophrenia
date
Prior art date
Application number
AT95924223T
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE216891T1 publication Critical patent/ATE216891T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95924223T 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie ATE216891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia
PCT/EP1995/002289 WO1995034306A1 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
ATE216891T1 true ATE216891T1 (de) 2002-05-15

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924223T ATE216891T1 (de) 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie

Country Status (11)

Country Link
US (1) US5912250A (de)
EP (1) EP0772442B1 (de)
JP (1) JPH10501257A (de)
AT (1) ATE216891T1 (de)
AU (1) AU704355B2 (de)
BR (1) BR9508021A (de)
CA (1) CA2192822C (de)
DE (1) DE69526584T2 (de)
ES (1) ES2176331T3 (de)
IL (1) IL110011A (de)
WO (1) WO1995034306A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
WO1999020273A1 (en) * 1997-10-17 1999-04-29 The Rockefeller University Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
EP1535616B1 (de) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Mittel zur behandlung des integrationsdysfunktionssyndroms
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
AU2881995A (en) 1996-01-05
JPH10501257A (ja) 1998-02-03
DE69526584T2 (de) 2002-11-14
EP0772442A1 (de) 1997-05-14
ES2176331T3 (es) 2002-12-01
EP0772442B1 (de) 2002-05-02
CA2192822C (en) 2007-04-03
BR9508021A (pt) 2004-04-20
WO1995034306A1 (en) 1995-12-21
IL110011A0 (en) 1994-10-07
AU704355B2 (en) 1999-04-22
CA2192822A1 (en) 1995-12-21
US5912250A (en) 1999-06-15
DE69526584D1 (de) 2002-06-06
IL110011A (en) 2004-09-27

Similar Documents

Publication Publication Date Title
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
BR9508295A (pt) Utilização de compostos de tiazol e tiadiazol composto composição farmacêutica e processos para preparar um composto e tratar distúrbios que respondem a ligantes de receptor d3 de dopamina
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
TW324662B (en) Benzamide-containing pharmaceutical composition
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
IL113024A (en) Quinazolinyl-amino derivatives having alpha-antagonist activity their preparation and pharmaceutical compositions comprising them
ATE179164T1 (de) Hiv-proteaseinhibitoren
DE69728536D1 (de) Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE143946T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
ES2150400A6 (es) Una composicion para el tratamiento de desordenes ulcerosos del tracto gastrointestinal.
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
ATE221068T1 (de) Anellierte beta-carboline